UnitedHealth Group Incorporated (NYSE:UNH) is one of the most undervalued blue chip stocks to buy according to hedge funds. J.P. Morgan analyst Lisa Gill assigned an Overweight rating to UnitedHealth Group Incorporated (NYSE:UNH) with a $418 price target, suggesting that the company could rebound by 48% in the coming 12 months.
A senior healthcare professional giving advice to a patient in a clinic.
She stated that the company’s shift from “unaware” in February to “proactively cooperating” with the Department of Justice isn’t surprising, as she views the company’s engagement as part of a broader defense of its practices. The analyst expressed an optimistic outlook for UnitedHealth Group Incorporated (NYSE:UNH), noting:
“While we are not lawyers, we note that if the court were to view this case similarly to previous ones brought forth by the DOJ regarding the False Claims Act (FCA), we believe that this would place the burden of proof on the DOJ to prove improper coding.”
UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments, which have solid operations.
While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
